Licensing In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer to fund Phase III ProMune trials for lung cancer under licensing pact valued at up to $505 mil., plus royalties. Medicis gains Botox competitor in $2.8 bil. Inamed purchase. Baxter gets U.S. rights to Cangene WinRho SDF for bleeding disorder. More licensing deals in brief